m7G-related genes predict prognosis and affect the immune microenvironment and drug sensitivity in osteosarcoma

Zili Lin1,2, Ziyi Wu3, Yuhao Yuan1,2

  • 1Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Pharmacology
|September 1, 2023
PubMed

Insights

This study reveals m7G modification

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Osteosarcoma (OS) presents therapeutic challenges due to multidrug resistance.
  • Understanding OS pathogenesis and progression is crucial for improved treatments.
  • m7G modification, a post-transcriptional process, offers potential insights into OS.

Purpose of the Study:

  • To investigate the m7G-related molecular landscape in osteosarcoma.
  • To identify prognostic biomarkers and therapeutic targets for OS.
  • To evaluate the therapeutic potential of AZD2014 in OS.

Main Methods:

  • Bioinformatic analyses including LASSO Cox regression and immune infiltration assessment.
  • Drug sensitivity analysis to identify potential therapeutic agents.
  • Experimental validation of m7G-related genes and AZD2014 efficacy via apoptosis and cell cycle assays.

Main Results:

  • An eight-signature m7G-related risk model was developed, correlating with immune infiltration and drug sensitivity.
  • AZD2014 demonstrated therapeutic potential by inducing apoptosis and G1-phase cell cycle arrest in OS cells.
  • CYFIP1 and EIF4A1 were identified as independent prognostic factors for OS.

Conclusions:

  • m7G-related genes significantly contribute to osteosarcoma pathogenesis.
  • AZD2014 shows promise as a therapeutic agent for OS.
  • CYFIP1 and EIF4A1 are validated independent risk factors, offering new avenues for OS treatment.